Abbott shares draw attention after revenue rose 13% and full-year adjusted EPS guidance was raised.
Stock Earnings Results
July 16, 2026
Table of Contents
July 16, 2026
Abbott Laboratories (NYSE: ABT) reported second-quarter 2026 results above expectations, supported by higher sales, stronger adjusted earnings, Medical Devices growth, and raised full-year adjusted EPS guidance.
Abbott is a global healthcare company with businesses in medical devices, diagnostics, nutrition, and established pharmaceuticals. Its products include continuous glucose monitors, cardiovascular devices, diagnostic tests, nutrition products, and branded generic medicines.
The company reported adjusted EPS of $1.31, above estimates of $1.28, representing a 2.3% earnings surprise. Revenue came in at $12.59 billion, above estimates of $12.48 billion, with reported sales growth of 13.0%.
Second-quarter sales increased 13.0% on a reported basis to $12.59 billion.
Comparable sales increased 4.8%.
GAAP diluted EPS was $0.53, while adjusted diluted EPS was $1.31.
Adjusted EPS increased 4.0% from $1.26 in the prior-year quarter.
Abbott said the quarter reflected improving momentum, with management expecting faster sales and earnings growth in the second half of the year.
Medical Devices sales increased 9.0% on a reported basis and 8.4% on a comparable basis.
Growth was led by low-teens growth in Electrophysiology and high-single-digit growth in Rhythm Management, Diabetes Care, and Heart Failure.
Diabetes Care sales increased 10.5% on a reported basis, with continuous glucose monitor sales rising 11.0% reported and 9.5% comparable.
Diagnostics sales increased 42.3% on a reported basis, helped by the Exact Sciences acquisition. Comparable Diagnostics sales increased 2.9%.
Established Pharmaceuticals sales increased 8.4% on a reported basis and 8.7% on a comparable basis, led by key emerging markets.
Nutrition sales declined 3.1% on a reported basis and 3.6% on a comparable basis, reflecting lower volumes and pricing actions.
Abbott completed enrollment in its TECTONIC U.S. pivotal trial for its investigational coronary intravascular lithotripsy system.
The company presented new clinical data across its pulsed field ablation and conduction system pacing portfolios.
Abbott also secured CE Mark for Libre Duo, described by the company as the world’s first dual glucose-ketone biowearable sensor.
The company completed its FDA submission for the Amulet 360 left atrial appendage device.
In diagnostics, updated American Cancer Society colorectal cancer screening guidelines reaffirmed Cologuard and Cologuard Plus as preferred screening options for average-risk adults age 45 and older.
Abbott reaffirmed its full-year 2026 comparable sales growth guidance of 6.5% to 7.5%.
The company raised its full-year adjusted diluted EPS guidance to $5.45 to $5.60, compared with its prior range of $5.38 to $5.58.
For the third quarter, Abbott expects adjusted diluted EPS of $1.38 to $1.46.
Abbott also returned $2.1 billion to shareholders in the second quarter through dividends and share repurchases.
Investors are likely watching Medical Devices growth, Diabetes Care momentum, Diagnostics growth after the Exact Sciences acquisition, Nutrition weakness, comparable sales growth, adjusted EPS guidance, share repurchases, and product pipeline progress.
The earnings beat was modest, but the raised EPS outlook and continued Medical Devices momentum were the key positives.
Abbott delivered a steady quarter with stronger reported sales and a higher earnings outlook.
The company beat EPS and revenue estimates, reaffirmed comparable sales growth guidance, and raised full-year adjusted EPS guidance. Medical Devices remained the strongest segment, while Diagnostics benefited from the Exact Sciences acquisition and Established Pharmaceuticals continued to grow in emerging markets.
The main weak spot was Nutrition, which remained under pressure from lower volumes and pricing actions.
Platforms like LevelFields track earnings beats, layoffs, dividend increases, leadership changes, dividend updates, and stock reactions together, helping investors identify when healthcare stocks are moving on real operating momentum.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better investor.
AI scans for events proven to impact stock prices, so you don't have to.
LEARN MORE